含铋剂四联疗法对慢性胃溃疡患者炎性因子的影响研究

目的 探讨含铋剂四联疗法在慢性胃溃疡患者中的临床效果及对炎性因子的影响。方法 选择2019年6月—2020年3月慢性胃溃疡患者138例为对象，随机数字表法分为两组，各69例。对照组采用兰索拉唑肠溶片、呋喃唑酮联合阿莫西林治疗，观察组在对照组基础上联合含铋剂四联疗法治疗，治疗6周后对患者进行6个月随访，比较两组消化道综合症状、炎性因子、安全性、复发率及GAS、SS水平。结果 观察组治疗6周后上腹部疼痛、嗳气、反酸、腹胀及胃灼热评分低于对照组，差异有统计学意义（P<0.05）；两组治疗后6周炎性因子得到明显降低；观察组治疗6周后IL-1、IL-6、IL-8及TNF-α低于对照组，差异有统计学意义（P <0.05）；两组用药期间低血压、肝肾异常及腹泻发生率差异无统计学意义（P> 0.05）；观察组治疗后6个月复发率低于对照组，差异有统计学意义（P <0.05）；两组治疗6周后GAS、SS低于对照组，差异有统计学意义（P <0.05）。结论 含铋剂四联疗法用于慢性胃溃疡患者中能降低消化道综合症状，可改善患者炎性因子水平，复发率较低，未增加药物不良反应发生率，改善患...

Effect of Bismuth Containing Quadruple Therapy on Inflammatory Factors in Patients With Chronic Gastric Ulcer

Objective To investigate the clinical effect of bismuth-containing quadruple therapy in patients with chronic gastric ulcer and its influence on inflammatory factors. Methods A total of 138 patients with chronic gastric ulcer from June 2019 to March 2020 were selected as subjects, and they were divided into two groups by random number table method, with 69 cases in each group. The control group was treated with lansoprazole enteric-coated tablets, furazolidone and amoxicillin, and the observation group was treated with bismuth-containing quadruple therapy on the basis of the control group. After 6 weeks of treatment, the patients were followed up for 6 months to compare the digestion tract syndrome, inflammatory factors, safety,recurrence rate and GAS and SS levels of the two groups. Results The upper abdominal pain, belching, acid reflux, abdominal distension, and heartburn scores of the observation group were lower than those of the control group at 6 weeks after treatment, the difference was statistically significant(P < 0.05);the inflammatory factors were significantly reduced after 6 weeks of medication intervention in the two groups;the observation group after 6 weeks of treatment IL-1, IL-6, IL-8 and TNF-α were lower than those in the control group, the difference was statistically significant(P < 0.05);the incidence of hypotension, liver and kidney abnormalities and diarrhea during the treatment of the two groups was not statistically significant(P > 0.05);the recurrence rate at 6 months after treatment of observation group was lower than that of the control group, the difference was statistically significant(P < 0.05);the GAS and SS of the two groups were lower than the control group after 6 weeks of treatment, the difference was statistically significant(P < 0.05). Conclusion The use of bismuth quadruple therapy in patients with chronic gastric ulcer can reduce gastrointestinal syndrome,improve the level of inflammatory factors in the patient, with a lower recurrence rate, without increasing the incidence of adverse drug reactions, and improving the serum gastrin and serum gastrin in patients. The level of somatostatin is worthy of promotion and application.